InMed Pharmaceuticals, Inc.’s (CSE: IN) (OTCQB: IMLFF) study, which generated an article published in the European Journal of Pain (http://nnw.fm/SVF1j), sets the stage for more research into how a topically-applied drug can provide relief of chronic or acute pain without central side effects, according to Dr. Sazzad Hossain, chief scientific officer of InMed.
Although the marijuana industry is comprised of some incredible companies, investors must be selective and focus on the real players.
Looking to gain an advantageous foothold in the burgeoning medical marijuana market, India Globalization Capital, Inc. (NYSE MKT: IGC) is developing innovative cannabis-based combination therapies that have application for both humans and animals.
India Globalization Capital, Inc. (NYSE MKT: IGC) is a first mover in developing a portfolio of products using cannabis-based “combination therapies” for the treatment of pain and other conditions.
The fastest-growing industry with the most consistent growth rate in North America is legal marijuana. A recent Forbes article says that the market could grow 700% by 2020.
At first blush, India Globalization Capital (NYSE: IGC) would seem a curiosity clothed in an enigma. Just how does a NYSE company move from a successful mining orientation to a pioneer in the development of multiple cannabinoid-based pharmaceutical therapies to treat pain and disease?
India Globalization Capital, Inc. (NYSE MKT: IGC), a Maryland-based company, is currently preparing four products for medical trials, including Hyalolex for the treatment of Alzheimer’s disease.
Changes in public opinion regarding cannabis have greatly fueled the fire blazing under the red-hot state-legalized marijuana market.
IGC has filed two patents, IGC-502 and IGC-505, for combination therapies for the treatment of seizures in dogs and cats, which in it itself is a surprisingly large market.
India Globalization Capital (NYSE MKT: IGC), an innovator in developing cannabis-based combination therapies to treat pain and other conditions, is currently applying the revolutionary seizure-treating potential of CBD to another population: domestic pets, and the company is addressing the 5 percent of dogs and just over 2 percent of cats in the United States that experience seizures.
Growing marijuana in North America, for obvious reasons, has historically been an underground affair. Amid growing legalization in favor of recreational and medicinal use, growing cannabis on mass scale is rapidly becoming a necessity for companies in a burgeoning industry driven by incredible consumer demand.
Most of the current research and development (R&D) surrounding cannabis revolves around understanding these biologically-active ingredients, especially cannabinoids.
With the North American cannabis market boasting an estimated worth of $7.2 billion in 2016, and new reports projecting CAGR of between 17 percent and 25 percent within the next few years, it’s certainly an exciting time to invest in the marijuana market.
With the market expanding and public support increasing, there are more opportunities to invest than ever before.
This inhibition has been a major obstacle for dispensaries and other cannabis-related businesses, but the use of bitcoin technology could be the key to overcoming the roadblock.
